China adopts revised patent law with Hatch-Waxman-like incentives for innovative drugs

Published date20 October 2020
Subject MatterPatents,Life Sciences,China,Hatch-Waxman,Innovation,Prescription Drugs,Generic Drugs,Patent Applications,Pharmaceutical Patents,Intellectual Property Protection,Pharmaceutical Industry
AuthorXin Tao,Philip Katz
Law FirmHogan Lovells

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT